Bridger Management LLC Takes Position in LifeStance Health Group, Inc. $LFST

Key Points

• Bridger Management LLC has acquired 389,700 shares of LifeStance Health Group, valued at approximately $2.6 million, making it the firm's 20th largest holding.
• LifeStance reported a quarterly revenue of $345.31 million, surpassing estimates and showing a year-over-year growth of 10.6%.
• Wall Street analysts have generally given the stock a Moderate Buy rating, with an average price target of $8.50, reflecting positive sentiment towards its future performance.

Bridger Management LLC purchased a new position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 389,700 shares of the company's stock, valued at approximately $2,595,000. LifeStance Health Group makes up about 1.3% of Bridger Management LLC's investment portfolio, making the stock its 20th biggest holding. Bridger Management LLC owned 0.10% of LifeStance Health Group as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in LFST. DekaBank Deutsche Girozentrale bought a new position in LifeStance Health Group during the first quarter valued at approximately $31,000. Xponance Inc. bought a new position in LifeStance Health Group during the first quarter valued at approximately $69,000. Ameriprise Financial Inc. bought a new position in LifeStance Health Group during the fourth quarter valued at approximately $87,000. Kapitalo Investimentos Ltda bought a new position in LifeStance Health Group during the first quarter valued at approximately $87,000. Finally, Forum Financial Management LP bought a new position in LifeStance Health Group during the fourth quarter valued at approximately $110,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Price Performance

NASDAQ LFST traded down $0.10 on Friday, hitting $5.37. 1,075,763 shares of the company were exchanged, compared to its average volume of 2,961,235. The firm has a 50 day moving average of $4.77 and a two-hundred day moving average of $5.83. The company has a market cap of $2.09 billion, a P/E ratio of -107.40 and a beta of 1.17. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $345.31 million for the quarter, compared to the consensus estimate of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts predict that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group lifted their price target on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. BTIG Research started coverage on shares of LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 price objective on the stock. Finally, Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

Insiders Place Their Bets

In other LifeStance Health Group news, major shareholder Summit Partners L. P sold 8,407,643 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the sale, the insider directly owned 33,524,715 shares of the company's stock, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Darren M. Black sold 8,407,643 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the sale, the director directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 20,407,643 shares of company stock valued at $103,466,750. 3.20% of the stock is currently owned by insiders.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.